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Abstract
Next generation sequencing studies have drawn the general landscape of breast cancers and identified hundreds
of new, actual therapeutic targets. Two major signaling pathways seem to be altered in a vast proportion of breast
cancers. The PI3 kinase/AKT pathway is activated and the JUN/MAPK pathway is repressed. Via the regulation of the
cell cycle this metabolic switch impacts on the balance between self-renewal, proliferation and differentiation of
the tumor-initiating cells
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Background
Recent results from next generation sequencing (NGS)
studies have established the repertoire of driver gene
mutations and copy number alterations (CNA) in breast
cancer [1-4]. Nearly 900 cancers representative of all
major expression subtypes (basal, luminal A and B,
ERBB2 and normal-like) have been studied. Many recur-
rent mutations have been uncovered. Mutations in
TP53, PIK3CA, GATA3 and PTEN genes are among the
most frequent. These studies have forever changed our
understanding of mammary oncogenesis.
Hypothesis
Many studies will extend these pioneering ones but it is
already possible to speculate further on the NGS data.
Data analysis revealed that some alterations (CNA and/
or mutations) never occur in the same tumor, i.e. are
mutually exclusive [1-4]. Two main signaling pathways
seem to be targeted, the PI3K/AKT pathway and the JUN/
MAPK pathway [1-4]. Alterations in components of the
PI3K/AKT pathway (PIK3CA, PIK3R1, AKTs, PTEN,
INPP4B…) are mutually exclusive but strikingly, amplifi-
cation and upregulation of genes encoding receptor-type
tyrosine kinases (RTKs) (IGF1R, EGFR, ERBB2) are also
(globally) mutually exclusive with alterations of the PI3K/
AKT pathway. This suggests that the primary role of RTK
amplification or mutation is to activate the PI3K/AKT
pathway. Thus, in the normal mammary epithelium these
RTKs are repressed or expressed at a low level and their
signaling is primarily oriented toward the JUN/MAPK
pathway, whereas when upregulated in tumor cells they
stimulate the PI3K/AKT pathway. To obtain this dosage
effect could be the reason for the amplification of ERBB2
and FGFR1 genes, although there could be other reasons
[5]. It is known that the PI3K/AKT pathway is activated in
tumors with mutated EGFR or overexpression of ERBB2
and determines the response to ERBB targeted inhibitors
[6]. Within the JUN/MAPK pathway alterations of the
components are also mutually exclusive [1]. Components
of the JUN/MAPK pathway are inactivated by deletions
and mutations, such as MAP2K4 and MAP3K1, or by am-
plifications, such as PAK1. Most importantly, alterations
leading to the activation of the PI3K/AKT pathway and
those leading to the inactivation of the JUN/MAPK path-
way are mutually exclusive [1]. Finally, not only mutations
and genomic rearrangements affect genes encoding com-
ponents of the two pathways but opposite modifications
in expression patterns of these genes could also participate
to their switch in breast cancer.
Our hypothesis is that one important consequence of
mutations, CNA and modifications of expression is to
shift cell signaling in the targeted mammary epithelial
cell from an active “JUN/MAPK pathway – inactive
PI3K/AKT pathway” state to an active “PI3K/AKT path-
way – inactive JUN/MAPK pathway” state.
Testing the hypothesis
In the diagram shown in Figure 1 we have represented
19 KEGG metabolic and signaling pathways and cell
processes altered by mutations in their components in
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the 602 breast cancer samples of the NGS studies for
which the molecular subtype had been assigned [1-4].
All pathways and processes are altered, although to dif-
ferent extents. Many potential therapeutical targets can
be found in these pathways. Two main signaling path-
ways are targeted (Figure 2), the JUN/MAPK pathway
and the PI3K/AKT pathway [1-4]. Mutations in PTEN,
amplifications and mutations in PIK3CA and AKT
genes, the MAGI3-AKT3 gene fusion [3], activate the
PI3K/AKT pathway whereas mutations in MAP3K1,
MAP3K13 and MAP2K4 inactivate the JUN/MAPK
pathway. The PI3K/AKT and JUN/MAPK pathways are
intimately related and intricate. For example, AKT
activation inhibits MAP2K4. This interaction and the
mirror effect of the alterations on the two signaling
pathways suggest that the PI3K/AKT pathway stimu-
lates the growth of tumor cells whereas the JUN/MAPK
pathway has an opposite effect and that the two path-
ways are the two sides of the same coin.
The downstream effects of the activated PI3K/AKT
and inhibited JUN/MAPK pathways are multiple, but at
least two could be of primary importance for the behav-
ior of the tumor-initiating cell that fuels the tumor
growth. A first major effect could be on the cell cycle.
During the G1 phase of the cell cycle, a checkpoint be-
fore entering S phase, also called the restriction (R)
point, has been defined as an important cell cycle stage
controling various cell fates [8] (Figure 3). The G1 phase
of the cell cycle has been thus divided into an early, signal-
ing factor-dependent subphase, controled by D cyclins
and a late, factor-independent subphase, controled by E
cyclins and a fully inactivated (hyperphosphorylated) RB
protein. The JUN/MAPK signaling pathway plays a role in
the early G1 subphase, where the cell may be induced into
quiescence, senescence or committed to differentiation,
depending on the presence of external factors [9]. When
entering the late G1 subphase, quiescence, cell death or
differentiation are no longer options and the cell
Figure 1 Altered KEGG pathways in breast cancers. In the bar-plot depicting the proportion of cancer samples with altered pathways (19
pathways are listed in the x-axis) the y-axis represents the percentage of samples altered in a given pathway stratified by subtype (red for basal,
purple for ERBB2, blue for luminal A, cyan for luminal B, and green for normal-like). The analysis was done in 602 samples from different studies in
which the molecular subtype (using PAM50) was available (466 from ref. 1, 98 from ref. 2, 38 from ref. 3).
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progresses to S phase and then to either symetric (pro-
liferation) or asymetric (self-renewal) division. At the
level of the tumor-initiating cell, the PI3K/AKT pathway
could stimulate self-renewal and/or proliferation and
the JUN/MAPK pathway cell differentiation or cell cycle
arrest. A compromised JUN/MAPK pathway and consti-
tutively activated PI3K/AKT pathway could force the
cell to go through the R point and progress to S-phase.
In this scheme, amplification of cyclin D1 appears as a
particularity; however, it occurs mainly in luminal
tumors, which are the most differentiated and less pro-
liferative of all breast tumors. Combined cyclin D1 amp-
lification (or a mutation with similar effect) and PI3K/
AKT pathway would give luminal tumors their particu-
lar phenotype. In addition to the signaling pathways, the
P53 protein acts as an important checkpoint on the way
to the late G1 subphase. Inactivation of P53 (by way of
mutations or deletions of the TP53 gene, or another
mechanism such as the amplification of the MDM2
gene) is a prominent feature of all subtypes of breast
cancer. However, it is more frequent in aggressive breast
cancers, especially the basal cases, where alterations of
the PI3K/AKT and JUN/MAPK pathways are less pre-
dominant. Basal breast cancers display a rearranged
genome. P53 inactivation, which has consequences on
the stability of the genome beyond those that could re-
sult from an activation of signaling pathways, could be
the major cause of the basal phenotype.
A second major effect of PI3K/AKT pathway activa-
tion and JUN/MAPK inhibition is on the metabolism of
the tumor-initiating cells. The latter are particularly re-
sistant to oxidative processes and ROS production. The
PI3K/AKT pathway, beside its role on cell growth and
survival, regulates a number of metabolic processes
including cell glucose uptake and neoglucogenesis in
relation with nutrient availability and redox and energy
conditions. It plays an important role in the glycolytic
phenotype of tumors [10]. Forkhead transcription
Figure 2 Subnetwork representation of protein interactions based on 78 mutated genes in 602 breast cancers [1-3]. Gene networks
were inferred using the Reactome FI Cytoscape Plugin [7]. A total of 182 genes with more than 7 mutations in 602 breast cancer samples were
used. Among them, 78 (43%) were mapped in the subnetwork and subsequently clustered into 12 modules, six of which were greater than 4.
Finally, modules functions were assessed with pathway enrichment analysis (FDR < 0.05). Three main pathways can be recognized: the P53
pathway and DNA repair (14 genes/18%) in blue, the PI3K/AKT signaling pathway (13 genes/18%) in pink and the MAPK pathway (8 genes/10%)
in green.
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factors FOXO are downstream of the PI3K/AKT and
JUN/MAPK cascades. FOXOs play a major role in the
regulation of both the cell cycle and metabolism [11].
They prevent stem cells to accumulate ROS and allow
DNA repair or quiescence. FOXOs are activated by the
JUN kinase signaling pathway in the presence of oxida-
tive stress. Conversely, activation of the PI3K/AKT and
inhibition of JUN/MAPK pathways overrules the tumor
suppressive effect of FOXOs and allows G1 progression.
With respect to cell cycle and cell fate decisions FOXO
transcription factors could thus represent important in-
tegrators of the two signaling pathways that are pre-
dominantly altered in breast cancer. They are therefore
important targets in mammary oncogenesis. FOXO
genes have not been found among the most frequently
altered genes in breast cancer in NGS studies [1-4];
they are probably not directly targeted (yet, we have
recently found rare mutations and deletions of the
FOXO3 gene; Cornen et al., submitted). FOXOs func-
tions may also be modified but maintained to ensure
some degree of metabolic regulation in the tumor-
initiating cells. FOXOs and P53 act on the same cellular
processes and transcription programs, and are intim-
ately cross-regulated [11].
Implications of the hypothesis
The NGS studies have drawn the general landscape of
breast cancers and identified hundreds of new, actual
targets. Although the role of many of them needs clarifi-
cation, especially regarding the transcription factors (e.g.
GATA3, RUNX, NCORs…), two major signaling path-
ways seem to be altered. This is good news since strat-
egies to counter the consequences of pathway alterations
are known and could be improved. Inhibiting the PI3K/
AKT pathway appears as a paramount strategy to stop
tumor growth [12]. If it fails one could adopt a strategy
that takes into account both the PI3K/AKT and JUN/
MAPK pathways but because they are truly interrelated
this may not be helpful. Targeting additional alterations
or pathways (including synthetic lethal ones) [13] out-
side the PI3K/AKT and JUN/MAPK pathways could be
more successful.
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Figure 3 Hypothetical representation of opposite downstream effects of two signaling pathways on the G1 phase of the cell cycle in a
breast tumor-initiating cell. During the early G1 subphase the cell integrates signals that may lead it to several fates (differentiation, apoptosis,
senescence, quiescence, pause for DNA repair, progression to S phase) [8]. Inhibition of the JUN/MAPK pathway shortens the early G1 subphase
rendering the cell independent of differentiation and apoptotic factors. In the same time, activation of the PI3K/AKT pathway induces the cell to
progress to late G1 subphase beyond the restriction (R) point; the cell may then undergo symmetric (proliferation) or asymmetric (self-renewal)
division. In green: proteins with repressive effect, in red: proteins with activating effect.
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